Vraylar vs Abilify

Generic Availability and Cost
Abilify, brand name for aripiprazole, is available in generic form. Generics usually cost less and are covered more easily by insurance, so Abilify is more affordable for many patients. Vraylar is the brand name for cariprazine and currently does not have a generic version available in the United States. This makes Vraylar usually more expensive, but manufacturer coupons are available here to make it more affordable.  A valid commercial insurance plan is required for the coupon to work.

FDA-Approved Uses
Abilify is approved by the FDA to treat several conditions. These include schizophrenia, manic or mixed episodes in bipolar disorder, irritability in children with autism, and as an add-on treatment for major depressive disorder. It is also sometimes used to help with tic disorders.

Vraylar is FDA-approved for schizophrenia, manic or mixed episodes of bipolar I disorder, and depressive episodes of bipolar I disorder. In addition, it was recently approved as an add-on treatment for major depressive disorder.

How They Work
Both medications belong to the “atypical neuroleptic” group. They work by balancing brain chemicals, particularly dopamine and serotonin, but they do so in slightly different ways.

Abilify works as a partial agonist at dopamine D2 and D3 receptors. This means it can increase dopamine activity when levels are too low and reduce it when levels are too high. It also affects serotonin receptors which helps with mood regulation.

Vraylar works in a similar way but has a stronger effect on D3 receptors than Abilify. Since D3 receptors are linked to mood, motivation, and cognitive function, this difference may explain why some people respond better to Vraylar. Like Abilify, it also interacts with serotonin receptors to help balance mood and thought processes.

Benefits
Abilify can reduce hallucinations, delusions, and mood swings in people with schizophrenia and bipolar disorder. It is also effective at reducing irritability in autism and can boost the effectiveness of antidepressants in people with major depression. 

Vraylar is effective at controlling psychotic symptoms in schizophrenia, stabilizing mood during manic or mixed episodes, and improving depressive symptoms in bipolar disorder. 

Dosage and Administration
Abilify comes in several forms including tablets, an oral solution, orally disintegrating tablets, and injections. The specific dose depends on the condition being treated, and doctors typically start with a low dose and increase from there. The most common and cost effective tablets range from 2mg - 30mg. Depression and agitation symptoms are most commonly dosed on the lower end of the spectrum. Bipolar disorder and psychosis often require higher doses.

Vraylar is available as capsules that are taken once daily. Dosing usually begins at a low level and is gradually adjusted based on the patient’s response and tolerance. Vraylar capsules start at 1.5 - 6mg.  There are fewer dose options with Vraylar.

Common Side Effects and Safety
Both medications have the potential for side effects, though the exact experience varies from person to person.

For Abilify, common side effects include restlessness (known as akathisia), insomnia, nausea, constipation, dizziness, and sedation. Some people may also experience mild weight gain. Less common but more serious risks include movement disorders such as tardive dyskinesia, a rare but serious condition called neuroleptic malignant syndrome, and changes in impulse control such as compulsive gambling or spending. Abilify may also affect blood sugar and cholesterol levels, so physicians often monitor these over time.

For Vraylar, the most common side effects include restlessness, nausea, insomnia, fatigue, dizziness, and constipation. Some patients may feel more sedated or notice tremors. Vraylar has long-lasting active ingredients, so its effects can remain for weeks even after stopping or adjusting the dose. There is also a small, less understood risk of vision changes such as cataracts, so sporadic eye exams may be recommended. Vraylar on average has fewer side effects. The development of Vraylar is believed to be from adapting Abilify to make it more user-friendly.

Putting It All Together
When comparing the two, some clear differences stand out. Abilify has the advantage of being available in generic form which usually makes it more affordable and accessible. It also has a longer track record of use with approvals for schizophrenia, bipolar disorder, autism-related irritability, and as an add-on for depression.

Vraylar, although brand-only and more expensive, brings newer options to the table. It is approved for schizophrenia, both manic and depressive phases of bipolar I disorder, and as an add-on for use in major depressive disorder. Its stronger action at D3 receptors may give it an edge in treating certain symptoms like motivation and mood regulation.